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Preclinical studies have suggested statins have antiproliferative and anti-metastatic effects
on endometrial cancer cells. Similarly, most previous epidemiological studies have
reported a better prognosis of endometrial cancer in patients who used statins. In this
study, we explored the role of statins in the prognosis of endometrial cancer in women with
type 2 diabetes in a hospital-based cohort. This retrospective cohort consisted of 119
women with type 2 diabetes who were diagnosed and treated for endometrial cancer at
Oulu University Hospital, Finland, between 2007 and 2014. The patients were classified as
statin users (n  58) and nonusers (n  61) based on the type of medication they were using
at the time of endometrial cancer diagnosis. Statin use showed no association with
progression-free survival or overall survival in the whole cohort nor the subgroups with
type I or type II histology, in lower or higher body mass index groups, or at an early or
advanced stage. The results remained similar in the multivariate analysis after adjusting
for the patient’s age, cancer stage, and histology. Furthermore, statin use seemed not
to have any association with most of the prognostic factors at the time of endometrial
cancer diagnosis.
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INTRODUCTION
Endometrial cancer is the fifth most common cancer among women worldwide (Ferlay et al., 2019)
and the incidence is increasing mostly due to obesity (Raglan et al., 2019). Type 2 diabetes (T2D) is a
rapidly increasing chronic disease, and it has been estimated that more than 460 million adults have
diabetes, with more than 90% suffering from T2D (IDF Diabetes Atlas, 2019). T2D itself seems to be
an independent risk factor for endometrial cancer, although these two diseases also share some other
common risk factors in addition to obesity (Liao et al., 2014).
Most endometrial cancers are diagnosed at early stages (Morice et al., 2016), and the 5-year
survival rate is 95% in early endometrial cancer (Siegel et al., 2019). However, survival decreases to as
low as 16% in advanced cancer (Siegel et al., 2019). Traditionally, endometrial cancer is grouped into
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a better prognosis (Samarnthai et al., 2010). Type II endometrial
cancers are poorly differentiated, they have more commonly a
higher frequency of deep myometrial invasion and pelvic lymph
node metastases and decreased sensitivity to progesterone
(Suarez et al., 2017).
As drug development costs have significantly increased,
drug repositioning has become a more attractive option
(Kobayashi et al., 2019). Drug repositioning aims to
discover new efficacies and practices for existing drugs that
have already been demonstrated to be safe in humans and have
established pharmacokinetics through clinical use (Kobayashi
et al., 2019).
Patients with T2D have an increased risk of both
cardiovascular diseases and hypercholesterolemia, and are
widely treated with statin therapy. In Finland, 40% of
patients diagnosed with T2D have been found to use lipid-
lowering medication without diagnosis of coronary heart
disease, and the percentage of medication users increases to
73% in patients with coincident coronary heart disease (Vehko
et al., 2013). In Finnish national guidelines, the level of low-
density lipoprotein in plasma is recommended to be less than
2.5 mmol/L in patients with T2D regardless of other risk
factors and less than 1.8 mmol/L in those patients with
coincident coronary heart disease, cerebral arterial disease
or peripheral arterial disease and if the targets are not met
otherwise, statin therapy is recommended to be initiated (Type
2 diabetes: Current Care Guidelines, 2020). Statins are HMG-
CoA reductase inhibitors that block the formation of
cholesterol by inhibiting the mevalonate pathway. In
preclinical studies, statins seem to have antiproliferative and
anti-metastatic effect on endometrial cancer cells (Kato et al.,
2010; Schointuch et al., 2014). The possible anticancer effects
of statins are believed to be derived from the mevalonate
pathway, as the pathway produces biologically active
metabolites that contribute to tumor-cell proliferation,
survival, invasion, and metastasis (Thurnher et al., 2012).
Furthermore, the mutant p53 protein, which is present in
the majority of all cancers, upregulates the mevalonate
pathway supporting the anticancer role of statins (Thurnher
et al., 2012). Mutant p53 is common in type II endometrial
cancers but rare in type I endometrial cancers (Samarnthai
et al., 2010; Banno et al., 2014). Lipophilic statins seem to have
more anticancerous effects than hydrophilic statins (Kato et al., 2010).
This difference is mainly due to the differences in cell membrane
penetration, as lipophilic statins easily diffuse across the membranes,
while hydrophilic statins rely on active transport (Beckwitt et al.,
2018). In a recent meta-analysis, statin use was associated with both
better overall survival (OS) and lower cancer-related mortality (Li
et al., 2018). Furthermore, a Finnish register-based study reported
lower mortality in non-endometrioid endometrial cancer among
statin users in patients with T2D (Arima et al., 2018).
This retrospective study aimed to determine if statin use would
improve the prognosis of endometrial cancer in women with
T2D in a hospital-based cohort when more data of the possible




Our study population consisted of all women with T2D who were
histological diagnosed with and treated for endometrial cancer
at Oulu University Hospital in Finland between 2007 and 2014.
Women, whose statin use was not known, were excluded. Data
were obtained from the Oulu University Hospital records.
Information extracted from the records included the patient’s
age at diagnosis of endometrial cancer, parity, statin use,
antidiabetic medication, menopause age, the presence of fatty
liver, and body mass index (BMI). Cancer-related information
such as stage, histology, peritoneal cytology, myometrial
invasion, lymphovascular invasion (LVI), estrogen receptor
(ER) status, residual tumor after surgery, and adjuvant
treatment received was also obtained from the hospital
records. All endometrial cancer diagnoses were based on
histology, and stages were rechecked and fitted to the
current International Federation of Gynecology and
Obstetrics (FIGO) stages (Pecorelli, 2009). According to
their histologies, the cancers were categorized as type I and
type II cancers such that grades 1 and 2 endometrioid
endometrial and mucinous cancers were labeled as type I
cancers while grade 3 endometrioid, serous, clear cell,
mixed, and undifferentiated cancers and carcinosarcomas
were classified as type II cancers. Patients were categorized
as statin users if they had used statin at the time of endometrial
cancer diagnosis or cancer surgery.
The follow-up of the patients began at the time of endometrial
cancer surgery, except for patients who were not eligible for
surgery (n  14). In those cases, the start of the follow-up was the
date of the diagnosis of endometrial cancer in the endometrial
biopsy. Follow-up ended at the time of death or closure of the
follow-up period (August 7, 2018). The median follow-up time
was 63 months.
Statistical Methods
Statistical analysis was performed using IBM SPSS Statistics,
version 25 (IBM Corporation, Armonk, NY, United States) and
GraphPad Prism, version 8.0.2 (GraphPad Software, San Diego,
CA, United States) software. Comparisons between statin users
and nonusers were evaluated using the two-sample t-test and
Mann–Whitney U test for continuous variables and Pearson
chi-square and Fisher’s exact tests for categorical variables.
The FIGO stages were distributed into two categories—early
and advanced. The early stage category included FIGO stages
IA and IB, while the advanced stage included stages II, III, and
IV. Kaplan–Meier curves with the log-rank test were applied to
the survival analysis. Progression-free survival (PFS) was
calculated from the time of the surgery to the date of
radiological progression. OS was calculated from the time of
surgery or cancer diagnosis to the time of death. Cox regression
analysis was applied for multivariate analysis—where age at
diagnosis, histology, and stage of endometrial cancer, along with
statin use, were included in the model. In all the statistical analyses,
p–values < 0.05 were considered statistically significant.
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RESULTS
In the chosen institution, there were 121 women with T2D
diagnosed with endometrial cancer between 2007 and 2014.
Two women were excluded from further analysis because of
the lack of information on their statin use. The statin user
group had 58 women while the statin nonuser group had 61
women. Patient characteristics were similar in both medication
groups. The mean age at diagnosis was 71.2 years among the
statin users and 70.9 years among statin nonusers (Table 1).
Median BMI was 34.0 in statin users and 35.5 in statin nonusers.
Menopausal status, parity, antidiabetic medication used, and
adjuvant treatment received were similar in both medication
groups.
Tumor characteristics were also quite similar in both
medication groups (Table 2). Most indicators of poor
prognoses, such as advanced stage, type II histology, and deep
myometrial invasion, were similar in both medication groups.
However, the presence of LVI was more common in statin users
than nonusers (p  0.028). Since most of the endometrial cancers
were endometrioid, ER was mostly positive in both medication
groups and showed no statistically significant difference. In
addition, peritoneal cytology and residual tumor after surgery
were similar in statin users and nonusers.
TABLE 1 | Patient characteristics in statin users and nonusers.
Statin
users (n = 58)
Statin
nonusers (n = 61)
p-value




Age group at diagnosis 0.19b
<65 years 12 19














Premenopausal 0 5 0.07b









Metformin ± other oral ADM 32 26 0.33b
Insulin ± oral ADM 17 18






Vaginal brachytherapy 7 5
Intracavitary radiation 2 6





STD, standard deviation; BMI, body mass index; ADM, Antidiabetic medication; WPRT, Whole-Pelvic Radiation Therapy.
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As expected, PFS was notably worse in more advanced cancer
stage (p  0.000000000002), type II histology (p  0.000005),
deep myometrial invasion (p  0.0004) and presence of LVI
(p  0.00009) in univariate analysis (Figure 1). Older age (p  0.13),
BMI group (p  0.54) or ER status of the tumor (p  0.35) had no
association with PFS.
In the whole study cohort, statin use seemed not to have
association with PFS (p  0.29) in univariate analysis. In addition,
the results remained similar in the subgroup analysis, as statin use
was not associated with PFS in type I histology (p  0.88), type II
histology (p  0.20), early stage (p  0.67), advanced stage (p 
0.70), superficial myometrial invasion (p  0.36), deep
myometrial invasion (p  0.26), presence of LVI (p  0.92),
absence of LVI (p  0.87) (Supplementary Figure S1), ER-
positive cancers (p  0.25), ER-negative cancers (p  0.87),
higher BMI group (p  0.70), lower BMI group (p  0.09),
younger age group (p  0.85) or older age group (p  0.30).
In Cox regression analysis, the advanced stage was the only
variable associated with poorer PFS after adjusting for statin
use, histology, and patient’s age (Table 3).
Similar to PFS, univariate analysis showed that OS was worse
in those with type II histology (p  0.000002), advanced stage
(p  0.000012), older age (p  0.005), deep myometrial invasion
(p  0.000008), and the presence of LVI (p  0.0001) (Figure 2).
However, patient’s BMI at the time of diagnosis (p  0.94) and ER
status of the tumor (p  0.77) showed no association with OS.
Statin use was not associated with OS in the univariate analysis
of the whole study population (p  0.56). Similarly, statin use did
not have association with OS in subgroups of type I histology (p 
0.55), type II histology (p  0.67), early stage (p  0.34), advanced
stage (p  0.38), superficial myometrial invasion (p  0.22), deep
myometrial invasion (p  0.59), presence of LVI (p  0.69),
absence of LVI (p  0.73) (Supplementary Figure S2), lower
(<35 kg/m2) BMI class (p  0.81), higher (≥35 kg/m2) BMI class
(p  0.91), younger age group (p  0.57), older age group (p 
0.97), ER-positive cancers (p  0.44), or ER-negative cancers (p 
0.75), Furthermore, Cox regression analysis showed that statin
use was not associated with OS after adjusting for histology type,
stage and patient’s age [Hazard ratio (HR) 0.995, 95% confidence
interval (CI): 0.50–2.00; Table 3].
DISCUSSION
In our study, statin use did not have an association with PFS or
OS in patients with T2D diagnosed with endometrial cancer
either in the whole population or in the subgroups. In addition,
statin use showed no association with major prognostic factors of
endometrial cancer at the time of cancer diagnosis, although the
presence of LVI was more common among the statin users. Two
thirds of statin users had LVI in their tumors, compared to 44% of
LVI in nonuser group. Due to relatively low sample sizes in both
groups, confirmatory studies with larger material are warranted.
Most previous studies concerning statin use and prognosis of
endometrial cancer have not focused on women with T2D. The
only previous study which focused solely on women with T2D
was our study in which statin use was associated with lower
mortality from non-endometrioid endometrial cancer in a
nationwide database consisted of patients with T2D (Arima
et al., 2018). The proportion of women with T2D in previous
studies explored statin use have varied from 13 to 38%
(Nevadunsky et al., 2015; Yoon et al., 2015; Feng et al., 2016;
Sperling et al., 2018; Segev et al., 2020). The number of women
with T2D has not been reported in all studies (Lavie et al., 2013;
Sanni et al., 2017).
When assessing all the cancers, patients with diabetes have
lower OS and might be treated less aggressively probably due to
comorbidities (van de Poll-Franse et al., 2007). However, the
presence of diabetes did not seem to have an association with the
treatment received for endometrial cancer (van de Poll-Franse
et al., 2007). Patients with diabetes who are diagnosed with
endometrial cancer have increased all-cause mortality
compared to women without diabetes but this difference was
not seen in cancer-related mortality (Chia et al., 2007). Although
higher BMI (≥35 kg/m2) was not linked with poorer OS or PFS in
our study cohort, in a meta-analysis higher BMI (≥40 kg/m2) was
linked with increased all-cause mortality in patients with
endometrial cancer (Secord et al., 2016). In addition, a
previous study has reported BMI to be associated with
increased mortality from both all-causes and endometrial
TABLE 2 | Tumor characteristics in statin users and nonusers.
Statin
users (n = 58)
Statin
nonusers (n = 61)
p-value
Histology 0.56a
Type I 42 47
Type II 16 14
Stage 0.33a
Early (IA–IB) 38 44
Advanced (≥ II) 17 13
Missing 3 4
Deep MI


















No 53 46 0.11b
Yes 1 3
Missing 0 2
No surgery 4 10
aPearson’s chi-square test.
bFisher’s exact test.
MI, myometrial invasion; LVI, lymphovascular invasion; ER, estrogen receptor.
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cancer, while the presence of diabetes was found to increase
cancer-related mortality, especially among non-obese women in
both endometrioid and non-endometrioid histologies (Nagle
et al., 2018). Furthermore, women diagnosed with endometrial
cancer have increased cardiovascular mortality compared to the
general population (Felix et al., 2017).
Similarly to our study, some previous studies did not observe
any association between statin use and better prognosis in
endometrial cancer when all histologies were analyzed together
(Yoon et al., 2015; Sanni et al., 2017; Segev et al., 2020). However,
some other studies have reported lower mortality from
endometrial cancer in type II or non-endometrioid histology
(Nevadunsky et al., 2015; Feng et al., 2016; Arima et al., 2018),
while Sperling et al. (2018) observed decreased mortality from
endometrial cancer and other causes in statin users in both
endometrioid and non-endometrioid histologies. Furthermore,
Lavie et al. (2013) found better OS, irrespective of the histology in
patients who used statin only after an endometrial cancer
diagnosis. As previous studies suggest, statin’s beneficial effect
in endometrial cancer might be seen in only type II histology.
However, we were unable to analyze these two histology groups
separately due to the small number of type 2 histology (n  30) in
our cohort.
There are differences in mechanisms in cancer development in
type I and type II endometrial cancers (Banno et al., 2014), which
might also have an impact on treatment choices and prognosis.
Type I endometrial cancers are more common in premenopausal
or perimenopausal women and develop in an estrogen-depend
manner from atypical endometrial hyperplasia (Banno et al.,
2014). Therefore, those tumors are usually positive for both
estrogen and progesterone receptor and well-differentiated
with less frequent lymph node metastases, less myometrial
invasion and better prognosis (Banno et al., 2014). Contrary,
type II endometrial cancer develops more commonly among
postmenopausal women and estrogen-independently via de
novo carcinogenesis from normal endometrium without
FIGURE 1 |Kaplan–Meier curves demonstrate associations between (A) histology (B) stage (C) deepmyometrial invasion (D) presence of lymphovascular invasion
(E) age, or (F) statin use and progression-free survival.
TABLE 3 | The results of multivariate analysis.
Overall survival Progression-free survival
HR 95% CI p-valuea HR 95% CI p-valuea
Stage 2.173 1.01–4.69 0.048 15.842 4.21–59.53 0.00004
Histology 3.477 1.64–7.38 0.001 2.438 0.86–6.95 0.095
Age 1.063 1.02–1.11 0.009 0.995 0.94–1.06 0.858
Statin use 0.995 0.50–2.00 0.998 0.995 0.40–2.50 0.992
aCox regression analysis.
HR, hazard ratio; CI, confidence interval.
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precancerous lesions (Banno et al., 2014). Gene mutations
associated with type I endometrial cancer include mutations in
tumor suppressor gene PTEN, E-cadherin component β-catenin
and K-ras oncogene, while gene mutations in oncogeneHER2 and
tumor suppressor gene p53 are seen in type II endometrial
cancers (Banno et al., 2014). The common occurrence of p53
mutations in type II endometrial cancer could explain the
favorable effect of statins (Kobayashi et al., 2019).
Our cohort can be considered generally representative in
terms of prognostic factors, as type II histology, advanced
cancer stage, deep myometrial invasion, presence of LVI,
and older age were all poor prognostic factors in OS
analysis. Similarly, type II histology, advanced cancer
stage, deep myometrial invasion, and presence of LVI
predicted poorer PFS. Stage, the most prominent
prognostic factor of endometrial cancer, remains the only
significant prognostic factor in PFS after adjusting for
histology, age, and statin use.
Survival of patients with endometrial cancer in our study was
relatively low as only 66.4% of the patients were alive at the end of
our follow-up. In contrast, the average 5-year survival among
patients with endometrial cancer in Finland was reported as
81.4% (Finnish Cancer Registry, 2020). The lower survival in
our study population is mainly because patients with T2D have
more coincident diseases than the average population. This is
consistent with a previous study where the overall mortality in
endometrial cancer patients with pre-existing diabetes was found
to be high (Barone et al., 2008), although the association between
cancer-related mortality and diabetes was not robust (Tsilidis
et al., 2015).
The strengths of this study include reliable and precise data on
patient characteristics, cancer characteristics, and over five-year
median follow-up. We had data on the patient at the time of
endometrial diagnoses, such as BMI and parity, and cancer-
related data such as ER status and myometrial invasion, which
are usually lacking in register-based studies. However,
information on the cause of death was not available and the
sample size was rather small due to the single-institution
based data.
Weaknesses of this study are the lack of information on the
duration and severity of diabetes along with the dose of the
medications used, which might lead to a bias, as a longer duration
of diabetes is associated with increased cardiovascular mortality,
among other comorbidities (Zoungas et al., 2014). Information
on the cause of death was not available in the hospital records. In
addition, the cholesterol levels of the patients and whether the
goals in hypercholesterolemia treatment were met is not known
in our study. It seems that hypercholesterolemia itself is also
associated with neoplasia progression and dedifferentiation and
by reducing LDL cholesterol with diet or drugs it is plausible to
reduce endothelial activation and prevent interplay between the
inflammatory mediators (Mehta et al., 1997). Although we had no
information on the statin type that the patients used, it is known
that the majority of Finnish patients use lipophilic statins, mostly
simvastatin and atorvastatin (Arima et al., 2017). We lacked the
data of the duration and dose of statin therapy. Statin users used
statins at the time of endometrial cancer surgery or at time of
endometrial cancer diagnosis in those cases who were not eligible
for surgery. In this study, we presumed continuous statin
exposure after the cancer diagnosis, though we could not
FIGURE 2 |Kaplan–Meier curves demonstrate associations between (A) histology (B) stage (C) deepmyometrial invasion (D) presence of lymphovascular invasion
(E) age, or (F) statin use and overall survival.
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verify the duration of statin use through prescription data.
However, in the literature concerning breast cancer prognosis, it
has been observed that prediagnostic statin users are most likely to
continue statin use after cancer diagnosis (Borgquist et al., 2019).
The current knowledge from The Cancer Genome Atlas defined
four clinically distinct endometrial cancer types based on their p53
mutational burden, exonuclease domain of the DNA polymerase
epsilon (POLE) mutations and microsatellite instability (Cancer
Genome Atlas Research Network et al., 2013; Stelloo et al., 2016).
We were unable to recategorize our endometrial cancer cases
according to The Cancer Genome Atlas as POLE mutation
analysis is not yet available in every-day cancer diagnostics and
microsatellite instability (MSI) status was not analyzed in the primary
diagnostics in our patient group. Lack of information on p53
mutation status in our study is probably a minor limitation since
most grade 3 endometrioid carcinomas with p53 mutation would
anyway have a poor prognosis and belong to the type II cancer group.
To conclude, statin use was not associated with PFS or OS in
patients with T2D diagnosed with endometrial cancer.
Furthermore, statin use seemed not to have any association
with most of the prognostic factors at the time of endometrial
cancer diagnosis.
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